2024
Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejection
2023
Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study
Murakami N, Borges T, Win T, Abarzua P, Tasigiorgos S, Kollar B, Barrera V, Ho Sui S, Teague J, Bueno E, Clark R, Lian C, Murphy G, Pomahac B, Riella L. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study. American Journal Of Transplantation 2023, 23: 549-558. PMID: 36740193, PMCID: PMC10318113, DOI: 10.1016/j.ajt.2023.01.016.Peer-Reviewed Original ResearchConceptsLow-dose IL-2 therapyIL-2 therapySkin allograftsFace transplant recipientsTransplant recipientsIL-2Immune regulationLow-dose interleukin-2 (IL-2) therapyHigher acute rejection ratesLow-dose IL-2Face transplantationAcute rejection ratesCytotoxicity-associated genesDose interleukin-2Greater suppressive functionInterleukin-2 therapyAutoimmune hemolytic anemiaRegulatory T cellsNarrow therapeutic windowLife-changing procedureImmunological monitoringTim-3Peripheral bloodImmune modulationHemolytic anemia
2022
mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis
Eskandari SK, Allos H, Al Dulaijan B, Melhem G, Sulkaj I, Alhaddad JB, Saad AJ, Deban C, Chu P, Choi JY, Kollar B, Pomahac B, Riella LV, Berger SP, Sanders JSF, Lieberman J, Li L, Azzi JR. mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis. Frontiers In Immunology 2022, 13: 899975. PMID: 35757726, PMCID: PMC9229986, DOI: 10.3389/fimmu.2022.899975.Peer-Reviewed Original ResearchConceptsRegulatory T cellsT cellsHuman regulatory T cellsHost THumanized mouse modelPro-apoptotic pathwaysSkin allotransplantationClinical efficacyImmunosuppressive potencyIntracytoplasmic expressionTransplant fieldMouse modelCellular therapyHigh expressionTarget cellsRapamycin complex 1Lysosomal granulesFunctional effectsMechanistic targetPatientsApoptosisC-JunGranzymesDrug targetsS6K
2014
Hand transplants and the mandate for tolerance
Koulmanda M, Pomahac B, Fan Z, Murphy G, Strom T. Hand transplants and the mandate for tolerance. Current Opinion In Organ Transplantation 2014, Publish Ahead of Print: &na;. PMID: 25373855, PMCID: PMC4352932, DOI: 10.1097/mot.0000000000000138.Peer-Reviewed Original ResearchConceptsHand transplantationIL-2Hand transplantLow-dose IL-2IL-2-based therapyBalance of immunityDrug-free toleranceRegulatory T cellsUse of immunosuppressionRecent clinical trialsLife-long immunosuppressionInduction of toleranceNonhuman primate modelShort-term treatmentDrug minimizationPosttransplant periodInflammatory processClinical trialsPrimate modelT cellsPreclinical demonstrationComposite allograftsAdverse inflammationTransplantationTransplant